Oprah day in biotech: Re­ge­na­cy gets $30M, Ab­bisko gets $70M, Cas­tle Creek gets $75M

→ A young biotech in Waltham called Re­ge­na­cy an­nounced a $30 mil­lion Se­ries A, led by Co­bro Ven­tures and Tai­wa­nia Cap­i­tal Man­age­ment. The com­pa­ny was a spin­out from the biotech Acety­lon af­ter it sold it­self to Cel­gene in 2017. Re­ge­na­cy was giv­en par­tial rights to Acety­lon’s lead drug – ri­col­i­no­s­tat– in a cou­ple in­di­ca­tions, such as nerve pain, while Cel­gene pushed them for­ward in can­cer. The biotech will use the Se­ries A funds to push the drug in­to a Phase II proof-of-con­cept tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER